DEA Telemedicine Rules and TRT: What Brand Owners Need to Know Before Dec 31, 2026

DEA telemedicine

Share this article:

Let’s start with something that rarely makes it into a pitch deck. The federal rule that lets a clinician prescribe testosterone to a patient they’ve only met on video has an expiration date. It’s December 31, 2026. 

If you own a TRT telehealth brand, or you’re thinking about launching one, that date belongs on your wall. Not because the sky is falling. There’s a real chance the rules get extended or replaced before it arrives. But “a real chance” isn’t a business plan. 

So here’s what we know as of November 6, what we don’t, and what we’d do if this were our brand. 

The 60-second version 

• Testosterone is a Schedule III controlled substance, so federal telemedicine rules apply to it in ways they don’t for estrogen or progesterone. 

• DEA’s temporary flexibilities, which allow prescribing without a prior in-person visit, run through December 31, 2026. 

• The permanent fix, called special registration, is still only a proposal. A final version has been under White House review since August 25, 2026 and, as of late October, had not been published. 

• If nothing is in place on January 1, patients who have never been seen in person could no longer be newly prescribed testosterone remotely under the federal baseline. • Brand owners have one extra question: could your company count as a “telemedicine platform” under the new rules? 

Why testosterone is the odd one out 

Most hormone therapy, like estradiol and progesterone, isn’t a controlled substance. Testosterone is. That one fact changes your legal homework. 

A federal law called the Ryan Haight Act generally says that before a clinician prescribes a controlled substance over the internet, they need to have evaluated the patient in person. There are exceptions. Since the pandemic, the biggest one has been a set of temporary DEA flexibilities that let registered practitioners skip that first in-person visit. DEA has extended them four times. The latest extension took effect on January 1, 2026.

What’s in force today 

Under the current extension, a DEA-registered practitioner can prescribe Schedule II through V controlled substances by telemedicine without seeing the patient in person first. The prescription has to serve a legitimate medical purpose and go through an interactive telecommunications system, and it all has to comply with federal and state law. The extension itself adds no new requirements. 

State rules sit on top of that, and some states are stricter, for example by limiting which controlled-substance schedules can be prescribed through telehealth. Federal permission is never the whole answer. 

What’s coming: special registration 

In January 2025, DEA proposed a permanent route called special registration. Under the proposal there are three types: 

• Telemedicine Prescribing Registration for Schedules III through V without a prior in-person visit. As proposed, testosterone would fit here. 

• Advanced Telemedicine Prescribing Registration for Schedules II through V, limited to certain specialties. 

• Telemedicine Platform Registration for entities that facilitate telemedicine prescribing between practitioners and patients. 

The proposal also floated state-by-state telemedicine registrations for prescribers, a prescription drug monitoring program check before each prescription, and photo ID verification. DEA received more than 6,400 comments, and the administration has changed since then. 

In August, the final rule went to the White House Office of Information and Regulatory Affairs for review (RIN 1117-AB40). The federal agenda lists November 2026 for final action. As of the law-firm articles we read, dated October 21 and October 27, the text still wasn’t public. Everyone who has written about it says the same thing: don’t assume the final version matches the proposal. 

If the final rule has dropped by the time you read this, stop and read it. This post will be out of date.

Three ways this could go

What happens What it likely means for TRT What to do
A final rule is published before Dec 31New registrations and requirements. Effective date and any transition period are unknown until the text is out.Read the final text with counsel. Map it to your prescribers and your company.
DEA issues a fifth extensionMore of the same, until a new end date. DEA has done this four times, but hasn’t announced one.Use the breathing room to build your backup plan anyway.
Neither arrives in time The Ryan Haight baseline returns on January 1, 2027. Patients never evaluated in person can’t be newly prescribed testosterone remotely. Legal commentators say patients already seen in person are generally unaffected, but confirm that with counsel.Have an in-person evaluation path and a patient transition plan ready to switch on.

One attorney we read expects a final rule or another extension before January 1. That’s an informed opinion, not a promise, and we’d plan accordingly. 

The part that’s different for brand owners 

Most DEA coverage is written for clinicians. If you own the brand, you’ve got an extra question to answer. 

The proposal would have DEA register entities it calls telemedicine platforms. Commentators who’ve read the draft say the definition covers platforms that meet criteria such as advertising controlled-substance prescribing, having financial ties to prescription volume, influencing prescribing decisions, or holding custody of prescriptions or records. They also note it was broad enough that a white-label brand, its software vendor, or both could be caught. The final text may narrow that. It may not. 

So don’t assume you’re out, and don’t assume you’re in. Ask your attorney to read your actual setup (how you advertise, how money moves, who holds patient records) against whatever definition ends up in the final rule. If any of your partner payments rise with prescription volume, flag that too, because it’s one of the factors in the proposal and a separate fee-splitting question in some states. 

And then there’s the very human problem. Picture a hypothetical member who paid for a three-month membership in December and can’t get a remote prescription in January. What do your terms say? What does your refund policy say? Most brands haven’t written that page yet. Now is a good time.

Your plan for the next few weeks 

Here’s what we’d do, in roughly this order. None of it is wasted if DEA extends the flexibilities again. 

1. Sort your patients into two piles. Those who have been evaluated in person by their current prescriber, and those who haven’t. Note each patient’s state. 

2. Check every prescriber’s DEA registration in every state where patients are located. 

3. Build the January 1 version of your patient flow now. That means an in-person evaluation option through your own clinic, partner clinics, or a hybrid model. If relief arrives, it cost you little. If it doesn’t, you’re ready. 

4. Rewrite your membership terms, renewal notices, and refund policy for the can’t-prescribe-remotely scenario. Keep consult fees and pharmacy charges separate so refund decisions stay clear. 

5. Capture the right data at intake: whether the patient has had an in-person evaluation, and the state they were in at each visit. 

6. Review state telehealth and controlled-substance rules: one state at a time.

7. Tell patients early, in plain language, if visits might need to change. 

8. Put one person on watch duty: the Federal Register, DEA’s Diversion Control Division site, and the OIRA review page for RIN 1117-AB40. 

One more thing: keep your marketing honest. “TRT delivered, no doctor visit ever” ages badly when rules change. FDA’s testosterone labeling is also specific: the products are approved for men with low testosterone tied to an associated medical condition, and the limitation of use for age-related hypogonadism remains. Your claims should match. 

Where a white-label platform fits, and where it doesn’t 

We’d be doing you a disservice if we told you a platform makes DEA rules go away. It doesn’t. No vendor can change what the law requires of prescribers, or of you. 

What a platform can do is take the build-it-yourself burden off your plate, so you can spend your energy on the compliance questions that actually matter. Homely MD is an all-in-one platform for healthcare providers: one contract and one invoice cover the white-label platform (patient portal, intake, scheduling, charting, e-prescribing, and unlimited video, audio, and chat), licensed clinicians across all 50 states, 24+ 503A compounding pharmacy partners, and integrated labs, including a ready-built TRT panel. You keep the brand, the patient relationships, and the patient data, with a free machine-readable data export within 30 days of termination. 

That makes it a practical foundation for a testosterone therapy telehealth platform. But before you sign with any white-label telehealth platform, including ours, ask these six questions: 

1. Which prescribers hold DEA registrations, and in which states?

2. How do you record whether a patient has had an in-person evaluation? 

3. What’s your plan if the flexibilities lapse on January 1? 

4. If a platform registration is required, how does the contract divide responsibility for it? 

5. What happens to my patients’ data and records if we part ways? 

6. How are refunds and cancellations handled if remote prescribing pauses? Ask these before you sign, not after. You’ll learn a lot from how directly the answers come back. 

How to start a TRT clinic (or a TRT telehealth brand) the sensible way 

If you’re figuring out how to start a TRT clinic or start a telehealth business around testosterone therapy, the DEA deadline doesn’t mean waiting. It means building with your eyes open: 

1. Choose a delivery model that survives a rule change. Telehealth-only is the most exposed. A hybrid model, with in-person evaluation available, is the most resilient. 

2. Get counsel early. Structure, DEA, state law, and your platform question all belong in the same conversation. 

3. Pick infrastructure that’s already built. A telehealth platform for testosterone therapy providers that bundles the technology, clinicians, pharmacy, and labs can get you live in as little as seven days, subject to onboarding and approvals. 

4. Let clinicians own the protocols, including monitoring. FDA’s updated testosterone labeling adds blood pressure warnings, so build that into your follow-up workflow. 

5. Launch small, in the states where you’re clearly compliant, and expand once the rules settle. 

A white label TRT telehealth program lets you do all of that under your own name, which is the whole point of a TRT telehealth brand. Confirm which services, formulations, and states are available at launch during onboarding. 

Planning a TRT program before December 31? 

Talk to Homely MD about launching your branded program in as little as seven days, subject to onboarding and approvals. 

Quick answers (FAQs) 

When do the DEA telemedicine flexibilities for testosterone end? 

December 31, 2026. DEA’s fourth temporary extension lets DEA-registered practitioners prescribe Schedule II-V controlled substances, including testosterone, by telemedicine without a prior in-person evaluation through that date. As of November 6, 2026, no final rule or fifth extension had been published. 

Can I prescribe TRT by telehealth after December 31, 2026? 

It depends on what DEA does first. If a final rule or another extension arrives, remote prescribing can continue under its terms. If neither does, patients never evaluated in person would need an in-person visit before a controlled-substance prescription. Legal commentators say patients already seen in person are generally unaffected. State law also applies. 

What is DEA special registration for telemedicine? 

It is DEA’s proposed permanent pathway for prescribing controlled substances by telemedicine. The January 2025 proposal has three registrations: telemedicine prescribing (Schedules III-V), advanced telemedicine prescribing, and telemedicine platform. A final rule has been under White House review since August 25, 2026. 

Does a TRT telehealth brand need a DEA registration? 

Prescribers need DEA registrations. The brand itself might fall under the proposed telemedicine platform registration, depending on the final definition and how your business operates, such as advertising, payments, and records custody. Have health care counsel review your actual setup once the final rule is published. 

What should a TRT telehealth brand do before December 31? 

Sort patients by whether they have had an in-person evaluation, confirm each prescriber’s DEA registration in every state served, build an in-person or hybrid path, update membership and refund terms, and monitor the Federal Register for the final rule or an extension. 

Disclaimer 

This article is for general information only and is not legal, medical, or regulatory advice. DEA rules are changing quickly, and state laws differ. Clinical decisions belong to licensed clinicians. Consult qualified health care regulatory counsel before launching or changing a program.

Share this post:

Related Articles

Uncategorized

FDA’s Interim Access Policy for Peptides: What It Means for Your Telehealth Peptide Program

For the last three years, building a telehealth peptide program meant operating in a gray zone. Many of the most

TRT Telehealth

How to Choose the Best TRT Telehealth Provider: A Guide for Healthcare Businesses

Men’s health is becoming an increasingly important part of the digital healthcare market. As more patients look for convenient access

HRT Telehealth Platform

HRT Telehealth Platform: A Guide for Hormone Therapy Providers

Hormone therapy is one of the fastest-growing areas of virtual care. Patients want convenient, ongoing support, and med spas, wellness